For decades, a large portion of American biopharmaceutical manufacturing has been based overseas. But in recent years, supply chain disruptions, fast-changing trade policies, and geopolitical uncertainty have spurred the multitrillion-dollar sector to make a strategic return stateside. In response to this reshoring effort, states are taking stock of their infrastructure and assessing whether they are ready to welcome these innovative organizations home.